Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Certolizumab pegol.

Gil Y Melmed, Stephan R Targan, Uma Yasothan

    Nature Reviews. Drug Discovery
    |August 2, 2008
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn's disease and ulcerative colitis.

    Crohn's & colitis 360·2026
    Same author

    Upfront medical or surgical treatment in Crohn's disease.

    The lancet. Gastroenterology & hepatology·2026
    Same author

    Ultrasound criteria for transmural healing and response in Crohn's disease: a systematic review of definitions and thresholds.

    Inflammatory bowel diseases·2026
    Same author

    Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study.

    Inflammatory bowel diseases·2026
    Same author

    Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusions.

    Respiratory medicine·2026
    Same author

    Intestinal Ultrasound for Monitoring Postoperative Crohn's Disease: A Review and Visual Atlas.

    Inflammatory bowel diseases·2025
    Same journal

    p38α inhibition restores axonal transport.

    Nature reviews. Drug discovery·2026
    Same journal

    Inflammatory bowel disease-on-a-chip.

    Nature reviews. Drug discovery·2026
    Same journal

    Designing GPCR-targeted miniproteins.

    Nature reviews. Drug discovery·2026
    Same journal

    Pulsatile FXR agonism.

    Nature reviews. Drug discovery·2026
    Same journal

    CRISPR strategy tackles bacterial toxin.

    Nature reviews. Drug discovery·2026
    Same journal

    Time to peak sales: how long is the climb?

    Nature reviews. Drug discovery·2026
    See all related articles

    Certolizumab pegol (Cimzia) is an FDA-approved treatment for moderate-to-severe Crohn's disease in adults. It is a tumor necrosis factor blocker for patients unresponsive to conventional therapies.

    Area of Science:

    • Immunology
    • Gastroenterology
    • Pharmacology

    Background:

    • Crohn's disease is a chronic inflammatory condition affecting the digestive tract.
    • Tumor necrosis factor (TNF) plays a key role in the inflammatory process of Crohn's disease.
    • Conventional therapies often fail to induce or maintain remission in patients with moderate-to-severe Crohn's disease.

    Discussion:

    • Certolizumab pegol is a humanized antibody fragment that targets TNF.
    • Its mechanism of action involves inhibiting TNF-alpha, a pro-inflammatory cytokine.
    • FDA approval in April 2008 marked a significant advancement in Crohn's disease treatment.

    Key Insights:

    • Certolizumab pegol offers a targeted therapy option for refractory Crohn's disease.
    • The drug provides an alternative for patients who have not responded to other treatments.

    Related Experiment Videos

  • Its approval expanded therapeutic choices for managing this complex condition.

    • Outlook:

    • Further research may explore long-term efficacy and safety profiles.
    • Potential for use in other autoimmune or inflammatory conditions.
    • Continued development of biologic therapies for inflammatory bowel disease.